Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease.
The purpose of this 20-week , open-label , r and omized clinical trial was to evaluate the effect of rosuvastatin on fasting serum lipids and lipoproteins , high-sensitivity C-reactive protein ( hs-CRP ) , and the glomerular filtration rate ( GFR ) in 91 patients with chronic kidney disease . Patients were r and omized to rosuvastatin 10 mg/day ( n = 48 ) or to  no lipid-lowering treatment ( n = 43 ) for 20 weeks . In contrast to patients not receiving rosuvastatin , patients receiving rosuvastatin tended to derive more favorable improvements from baseline values in low-density lipoprotein cholesterol ( -43 % , p < 0.001 , vs 7 % , p = NS ; p < 0.001 for change with rosuvastatin treatment vs change with no antilipemic treatment ) , hs-CRP ( -47 % , p < 0.001 , vs 7 % , p = NS ; p < 0.001 for change with rosuvastatin treatment vs change with no antilipemic treatment ) , and GFR ( 11 % , p < 0.05 , vs 4 % , p = NS ; p = NS for change with rosuvastatin treatment vs change with no antilipemic treatment )
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .